Literature DB >> 36187369

Immune checkpoint inhibitor-related liver toxicity.

Fabian J Bolte1, Richard D Hall2, Neeral L Shah3.   

Abstract

Content available: Audio Recording.
© 2022 American Association for the Study of Liver Diseases.

Entities:  

Year:  2022        PMID： 36187369      PMCID： PMC9512476          DOI： 10.1002/cld.1241

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  15 in total

1.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

Authors:  Eleonora De Martin; Jean-Marie Michot; Barbara Papouin; Stéphane Champiat; Christine Mateus; Olivier Lambotte; Bruno Roche; Teresa Maria Antonini; Audrey Coilly; Salim Laghouati; Caroline Robert; Aurélien Marabelle; Catherine Guettier; Didier Samuel
Journal:  J Hepatol       Date:  2018-02-08       Impact factor: 25.083

2.  Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma.

Authors:  David E Kleiner; David Berman
Journal:  Dig Dis Sci       Date:  2012-03-21       Impact factor: 3.199

3.  The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.

Authors:  Jean-Marie Michot; Ariane Lappara; Jérôme Le Pavec; Audrey Simonaggio; Michael Collins; Eléonora De Martin; François-Xavier Danlos; Samy Ammari; Cécile Cauquil; Stéphane Ederhy; Emmanuel Barreau; Rakiba Belkhir; Amandine Berdelou; Julien Lazarovici; Philippe Chanson; Hassan Izzedine; Andrei Seferian; Christine Le Pajolec; Capucine Baldini; Patricia Martin-Romano; Xavier Mariette; Caroline Robert; Benjamin Besse; Antoine Hollebecque; Andrea Varga; Salim Laghouati; Christine Mateus; Anne-Laure Voisin; Jean-Charles Soria; Christophe Massard; Aurélien Marabelle; Stéphane Champiat; Olivier Lambotte
Journal:  Eur J Cancer       Date:  2020-03-12       Impact factor: 9.162

4.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.

Authors:  Mar Riveiro-Barciela; Ana Barreira-Díaz; Judit Vidal-González; Eva Muñoz-Couselo; Fernando Martínez-Valle; Lluís Viladomiu; Beatriz Mínguez; Carolina Ortiz-Velez; Lluís Castells; Rafael Esteban; María Buti
Journal:  Liver Int       Date:  2020-06-03       Impact factor: 5.828

Review 6.  Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors.

Authors:  F Alessandrino; S H Tirumani; K M Krajewski; A B Shinagare; J P Jagannathan; N H Ramaiya; D N Di Salvo
Journal:  Clin Radiol       Date:  2017-05-02       Impact factor: 2.350

7.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

8.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.